对多发性硬化症口服治疗之间的临床,利用和成本结果进行比较
Patrick Racsa1, Claire Kiss1, Lauren Stevens1
1Humana, Louisville, KY (Racsa, Stevens, Ellis), at the time the study was conducted Humana Pharmacy Solutions, Humana Inc., Louisville, KY.
Journal of managed care & specialty pharmacy
|February 3, 2024
概括
芬戈利莫德 (FG) 在多发性硬化症 (MS) 患者的使用与与二甲基烟酸 (DMF) 和特里弗卢诺米德 (TERI) 相比,与更低的医疗保健资源利用率和更少的复发有关. 这项研究突出了FG的重点.
科学领域:
- 神经学 神经学
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 多发性硬化症 (MS) 在美国影响近100万个人,造成严重的残疾和经济负担.
- 口服疾病修饰疗法 (DMT) 越来越多地用于MS管理.
- 对早期口服MS治疗的临床结果和医疗资源利用的比较数据有限.
研究的目的:
- 为了比较临床结果,医疗保健资源利用率和医疗保险优势处方药 (MAPD) 和商业保险的MS患者之间的医疗保健资源利用率和成本,这些患者接受了用二甲基烟酸 (DMF),fingolimod (FG) 或 teriflunomide (TERI) 治疗.
主要方法:
- 使用Humana研究数据库 (2013-2018) 进行回顾性队列研究.
- 包括1442名患者,他们的第一个口服MS药物索赔 (DMF,FG或TERI).
- 随访患者至少12个月,使用治疗权重的逆概率 (IPTW) 进行对结果,资源利用和成本的比较分析.
主要成果:
- 与DMF和TERI相比,Fingolimod (FG) 组的治疗时间显著长,停药率较低.
- 与DMF和TERI相比,FG组的年复发率 (ARR) 显着较低.
- 与DMF和TERI相比,FG患者使用的医疗保健资源较少,包括住院住院和急诊室访问率显著降低.
结论:
- 多发性硬化症 (MS) 患者的芬戈利莫德 (FG) 治疗与医疗资源利用率的减少有关.
- 与DMF和TERI相比,FG治疗与年复发率 (ARR) 的降低有关.
- 这些发现表明FG在MS管理中的潜在经济和临床益处.
更多相关视频
08:18A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
Published on: December 26, 2015
17.4K
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
4.1K
相关概念视频
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Comparing the Survival Analysis of Two or More Groups
188
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
188
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
